KRRO
Korro Bio, Inc.NASDAQHealthcare$14.00+10.67%ClosedMarket Cap: $131.6M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.52
P/S
20.28
EV/EBITDA
-1.85
DCF Value
$-0.70
FCF Yield
-61.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.8%
Operating Margin
-1366.4%
Net Margin
-1834.5%
ROE
-115.9%
ROA
-103.3%
ROIC
-83.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.3M | $-50.0M | $-5.33 |
| FY 2025 | $6.4M | $-117.3M | $-12.48 |
| Q3 2025 | $1.1M | $-18.1M | $-1.92 |
| Q2 2025 | $1.5M | $-25.8M | $-2.74 |
Analyst Ratings
View AllCantor FitzgeraldOverweight
2026-03-13Raymond JamesOutperform
2026-03-13Clear StreetBuy
2026-02-19William BlairOutperform
2026-02-17Piper SandlerOverweight
2026-01-29Trading Activity
Insider Trades
View AllLynx1 Capital Management LP10 percent owner
BuyThu Apr 02
Lynx1 Capital Management LP10 percent owner
SellThu Apr 02
SANDELL SCOTT D10 percent owner
BuyThu Mar 12
SANDELL SCOTT D10 percent owner
BuyThu Mar 12
New Enterprise Associates 17, L.P.10 percent owner
BuyThu Mar 12
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.43
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.